Approaching drug discovery in a completely new way through a focus on novel and often overlooked drug targets.
We are a biotech company focused on developing medicines that address the broad spectrum of cancer.
1 in 6 deaths is due to cancer worldwide. Most therapeutics companies have focused their efforts on answering the question what is different in cancer cells?
We have taken a different approach, instead asking what is always the same in cancer cells? This led to our focus on oxidative stress and its role in disease.
Stemming from this question, NIH-funded research conducted over the span of ~40 years has led us to a major breakthrough in methods of killing cancer cells of many different types, all without damaging the body's normal cells.
Early research also indicates that similar approaches may be used to tackle a wide range of other metabolic diseases beyond cancer.
We have a particular interest in understanding how our novel targets translate oxidative stress into disease, and we have built a team of experts to translate our science from the lab to the patient.